BrainStorm Advances NurOwn ALS Program Toward Phase 3b
New York, United States, August 14, 2026 BrainStorm Cell Therapeutics Inc. announced its financial results for the second quarter...
myelodysplastic syndrome
Advertisement
Kyowa Kirin Advances AI-Powered Drug Discovery R&D
Tokyo, Japan, August 16, 2026 Kyowa Kirin Co., Ltd. has selected Cognizant and Benchling as partners to implement an...
Actinium Advances Actimab-A With Manufacturing Expansion
New York, United States, August 14, 2026 Actinium Pharmaceuticals, Inc. announced new intellectual property and manufacturing developments supporting its...
FDA Approves Tregzi to Prevent Chronic GVHD in Blood Cancer
SILVER SPRING, Maryland, June 30, 2026 The U.S. Food and Drug Administration (FDA) has approved Tregzi, the first regulatory...
FDA Approves Tregzi for Chronic GVHD Prevention in Blood Cancer
SILVER SPRING, Maryland, June 30, 2026 The U.S. Food and Drug Administration (FDA) has approved Tregzi, developed by Orca...
Advertisements
Samsung Bioepis Relaunches BYOOVIZ with Harrow in the U.S.
INCHEON, South Korea, July 1, 2026 Samsung Bioepis has officially announced the U.S. relaunch of BYOOVIZ® (ranibizumab-nuna), the first...
FDA Approves Tregzi to Prevent Chronic GVHD in Blood Cancer
SILVER SPRING, Md., June 30, 2026 The U.S. Food and Drug Administration (FDA) has approved Tregzi, the first regulatory...
TuHURA Files IND for TBS-2025 in AML and Blood Cancers
TAMPA, Fla., June 15, 2026 TuHURA Biosciences, Inc. has announced the filing of an Investigational New Drug (IND) application...
Amphista Therapeutics Receives FDA Clearance for AMX-883 AML Trial
CAMBRIDGE, UK, June 8, 2026 Amphista Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the...
Stelexis BioSciences Reports Breakthrough Phase 1 Eganelisib Results in AML and MDS
WALTHAM, Massachusetts, USA, June 2, 202 Stelexis BioSciences has announced encouraging Phase 1 clinical trial results for eganelisib, its...
Advertisement
